The firm is seeking damages and various injunctions, citing 11 different counts of fraud, breach of contract, tortious interference, and unfair competition.
The researchers reported that targeting HDAC4 in the patient-derived neurons appeared to correct the expression of genes that differed in the disease state.
The group aims to collect and sequence more than 2,500 blood samples by 2020 to improve primary diagnosis and treatment options for patients suffering from Parkinson's disease.
According to the researchers, led by a team at the University of Cambridge, detecting somatic brain mutations in patients during their life may increase diagnostic precision and lead to new therapies.
Centogene will collect dried blood spot samples and perform genetic analysis to find and recruit Parkinson's disease patients for Denali's LRRK2 inhibitor trials.
Scientific American reports that drugs being pursued to treat small fraction of Parkinson's disease patients with a certain gene mutation could also help a larger portion of patients.
